NPS Pharmaceuticals Given Consensus Rating of “Buy” by Analysts (NASDAQ:NPSP)
Shares of NPS Pharmaceuticals (NASDAQ:NPSP) have been given a consensus rating of “Buy” by the fifteen analysts that are covering the stock, American Banking & Market News reports. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $39.23.
A number of analysts have recently weighed in on NPSP shares. Analysts at Canaccord Genuity reiterated a “buy” rating on shares of NPS Pharmaceuticals in a research note on Friday, August 15th. Separately, analysts at FBR Capital Markets initiated coverage on shares of NPS Pharmaceuticals in a research note on Thursday, August 14th. They set an “outperform” rating and a $34.00 price target on the stock. Finally, analysts at Jefferies Group reiterated a “hold” rating on shares of NPS Pharmaceuticals in a research note on Thursday, August 7th. They now have a $26.00 price target on the stock, up previously from $25.00.
Shares of NPS Pharmaceuticals (NASDAQ:NPSP) opened at 30.18 on Thursday. NPS Pharmaceuticals has a 52-week low of $21.60 and a 52-week high of $39.68. The stock’s 50-day moving average is $28.55 and its 200-day moving average is $30.18. The company has a market cap of $3.216 billion and a price-to-earnings ratio of 1470.00.
NPS Pharmaceuticals (NASDAQ:NPSP) last posted its quarterly earnings results on Wednesday, August 6th. The company reported $0.02 earnings per share for the quarter. The company had revenue of $56.10 million for the quarter, compared to the consensus estimate of $53.06 million. During the same quarter last year, the company posted ($0.13) earnings per share. NPS Pharmaceuticals’s revenue was up 53.7% compared to the same quarter last year. Analysts expect that NPS Pharmaceuticals will post $0.03 EPS for the current fiscal year.
NPS Pharmaceuticals, Inc (NASDAQ:NPSP) is a biopharmaceutical company focused on pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.